secwatch / observer

8-K filed July 31, 2026, 4:50 PM ET ticker QNCX CIK 0001662774

leadership confidence high sentiment neutral materiality 0.75

Quince Therapeutics announces conditional CEO/COO resignations and appointments pending shareholder vote

Quince Therapeutics, Inc.

CEO Dirk Thye and COO Brendan Hannah tender conditional resignations effective two business days after Sept 25, 2026 special meeting, contingent on stockholder approval of three proposals.
Board conditionally appoints Brigette Roberts as CEO, John Militello as CFO, and Keith Fandrick as COO, effective at same time.
Board reduces size from 5 to 4 upon Thye's resignation; intends to appoint independent director.
Resignations and appointments tied to stockholder vote on conversion proposal, minimum price proposal, and authorized share increase to 275M.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Brendan Hannah

Chief Operating Officer, Chief Business Officer and Chief Compliance Officer

QNCX · Quince Therapeutics, Inc.

Effective: 2026-09-29
Successor: Keith Fandrick
Filed: July 31, 2026, 4:50 PM ET

each of Dirk Thye, the Chief Executive Officer and Chief Medical Officer of Quince Therapeutics, Inc. (the “ Company ”), and a member of the Company’s board of directors (the “ Board ”), and Brendan Hannah, the Company’s Chief Operating Officer, Chief Business Officer and Chief Compliance Officer, tendered conditional resignations from their positions with the Company

Appointed

John Militello

Chief Financial Officer

QNCX · Quince Therapeutics, Inc.

Effective: 2026-09-29
Filed: July 31, 2026, 4:50 PM ET

John Militello, CPA , age 52, was conditionally appointed as the Company’s Chief Financial Officer

Appointed

Brigette Roberts

Chief Executive Officer

QNCX · Quince Therapeutics, Inc.

Effective: 2026-09-29
Filed: July 31, 2026, 4:50 PM ET

Brigette Roberts, M.D. , age 50, was conditionally appointed as the Company’s Chief Executive Officer

Departed

Dirk Thye

Chief Executive Officer and Chief Medical Officer

QNCX · Quince Therapeutics, Inc.

Effective: 2026-09-29
Successor: Brigette Roberts
Filed: July 31, 2026, 4:50 PM ET

each of Dirk Thye, the Chief Executive Officer and Chief Medical Officer of Quince Therapeutics, Inc. (the “ Company ”), and a member of the Company’s board of directors (the “ Board ”), and Brendan Hannah, the Company’s Chief Operating Officer, Chief Business Officer and Chief Compliance Officer, tendered conditional resignations from their positions with the Company

Appointed

Keith Fandrick

Chief Operating Officer

QNCX · Quince Therapeutics, Inc.

Effective: 2026-09-29
Filed: July 31, 2026, 4:50 PM ET

Conditional Appointments of Brigette Roberts, John Militello and Keith Fandrick

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brendan Hannah resigned as Chief Operating Officer, Chief Business Officer and Chief Compliance Officer at Quince Therapeutics, Inc..

Action: resigned
Role: Chief Operating Officer, Chief Business Officer and Chief Compliance Officer

Exact text from the filing

each of Dirk Thye, the Chief Executive Officer and Chief Medical Officer of Quince Therapeutics, Inc. (the “ Company ”), and a member of the Company’s board of directors (the “ Board ”), and Brendan Hannah, the Company’s Chief Operating Officer, Chief Business Officer and Chief Compliance Officer, tendered conditional resignations from their positions with the Company

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

John Militello was appointed as Chief Financial Officer at Quince Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

John Militello, CPA , age 52, was conditionally appointed as the Company’s Chief Financial Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Brigette Roberts was appointed as Chief Executive Officer at Quince Therapeutics, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

Brigette Roberts, M.D. , age 50, was conditionally appointed as the Company’s Chief Executive Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dirk Thye resigned as Chief Executive Officer and Chief Medical Officer at Quince Therapeutics, Inc..

Action: resigned
Role: Chief Executive Officer and Chief Medical Officer

Exact text from the filing

each of Dirk Thye, the Chief Executive Officer and Chief Medical Officer of Quince Therapeutics, Inc. (the “ Company ”), and a member of the Company’s board of directors (the “ Board ”), and Brendan Hannah, the Company’s Chief Operating Officer, Chief Business Officer and Chief Compliance Officer, tendered conditional resignations from their positions with the Company

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.7

Keith Fandrick was appointed as Chief Operating Officer at Quince Therapeutics, Inc..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

Conditional Appointments of Brigette Roberts, John Militello and Keith Fandrick

View on SEC.gov

Quince Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-328784

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.